Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
_____________

FORM 8-K
_____________

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported):  September 23, 2009
 
Keryx Biopharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
(State or Other Jurisdiction
of Incorporation)
000-30929
(Commission File Number)
 
13-4087132
(IRS Employer Identification No.)
 
750 Lexington Avenue
New York, New York 10022
(Address of Principal Executive Offices)

(212) 531-5965
(Registrant's telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 
£
Written communications pursuant to Rule 425 under the Securities Act.
 
£
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
 
£
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
 
£
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
 
 
 
 
 
Item 8.01. 
Other Events.

On September 23, 2009, Keryx Biopharmaceuticals, Inc. (the “Company”) issued a press release announcing results of the Open Label Extension (OLE) to the Phase 2 study of Zerenex (ferric citrate) for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis. A copy of such press release is being filed as Exhibit 99.1 to this report and is incorporated herein by reference.


Item 9.01.  
Financial Statements and Exhibits.

(d) 
Exhibits.

The following exhibit is filed as a part of this report:
 
Exhibit
  
Number
Description
   
99.1
Press Release dated September 23, 2009.
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Keryx Biopharmaceuticals, Inc.
(Registrant)
  
     
     
     
Date:  September 23, 2009      
 
By:
/s/ James F. Oliviero  
   
James F. Oliviero
  
   
Chief Financial Officer
  
       
 

INDEX TO EXHIBITS


 
Exhibit
  
Number
Description
   
99.1
Press Release dated September 23, 2009.